Advertisement

Drug-Induced Microvesicular Steatosis and Steatohepatitis

  • Dominique Pessayre
  • Bernard Fromenty
  • Abdellah Mansouri
Chapter

Keywords

Valproic Acid Mitochondrial Permeability Transition Pore Mitochondrial Permeability Transition Pore Wilson Disease Tiaprofenic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ames, B. N., Shigenaga, M. K., and Hagen, T. M., 1993, Oxidants, antioxidants, and the degenerative diseases of aging, Proc. Natl. Acad. Sci. USA 90:7915–7922.PubMedGoogle Scholar
  2. Bailey, S. M., and Cunningham, C. C., 1998, Acute and chronic ethanol increases reactive oxygen species generation anddecreases viability infresh, isolated rat hepatocytes, Hepatology 28:1318–1326.CrossRefPubMedGoogle Scholar
  3. Bedossa, P., Houglum, K., Trautwein, C., Holstege, A., and Chojkier, M., 1994, Stimulation of collagen α(I) gene expression is associated with lipid peroxidation in hepatocellular injury: A link to tissue fibrosis? Hepatology 19:1262–1271.CrossRefPubMedGoogle Scholar
  4. Bernardi, P., Basso, E., Colonna, R., Costantini, P., Di Lisa, E, Eriksson, O., Fontaine, E., Forte, M., Ichas, F, Massari, S., Nicolli, A., Petronilli, V, and Scorrano, L., 1998, Perspectives on the mitochondrial permeability transition, Biochim. Biophys. Acta 1365:200–206.Google Scholar
  5. Berson, A., De Beco, V, Lettéron, P., Robin, M. A., Moreau, C., El Kahwaji, J., Verthier, N., Feldmann, G., Fromenty, B., and Pessayre, D., 1998, Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes, Gastmenterology 114:764–774.Google Scholar
  6. Bjorge, S. M., and Baillie, T. A., 1985, Inhibition of medium-chain fatty acid β-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid, Biochem. Biophys. Res. Commun. 132:245–252.CrossRefPubMedGoogle Scholar
  7. Bravo, J. F, Jacobson, M. P., and Mertens, B. F, 1977, Fatty liver and pleural effusion with ibuprofen therapy, Ann. Intern. Med. 87:200–201.PubMedGoogle Scholar
  8. Casini, A., Pinzani, M., Milani, S., Grappone, C.. Galli, G., Jezequel, A. M., Schuppan, D., Rotella, C. M., and Surrenti, C., 1993, Regulation of extracellular matrix synthesis by transforming growth factor β1 in human fat storing cells, Gastmenterology 105:245–253.Google Scholar
  9. Chance, B., Sies, H., and Boveris, A., 1979, Hydroperoxide metabolism in mammalian organs, Physiol. Rev. 59:527–605.PubMedGoogle Scholar
  10. Chen, C. H., and Cheng, Y. C., 1989, Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine, J. Biol. Chem. 264:11934–11937.PubMedGoogle Scholar
  11. Curzio, M., Esterbauer, H., and Dianzani, M. U, 1985, Chemotactic activity of hydroxyalkenals on rats neutrophils, Int. J. Tissue React. 7:137–142.PubMedGoogle Scholar
  12. Danan, G., Trunet, P., Bernuau, J., Degott, C., Babany, G., Pessayre, D., Rueff, B., and Benhamou, J. P., 1985, Pirprofen-induced fulminant hepatitis, Gastroentemlogy 89:210–213.Google Scholar
  13. Deboyser, D., Goethals, F., Krack, G., and Roberfroid, M., 1989, Investigation into the mechanism of tetracycline-induced steatosis: Study in isolated hepatocytes, Toxicol. Appl. Pharmacol. 97:473–179.CrossRefPubMedGoogle Scholar
  14. Deschamps, D., Fisch, C., Fromenty, B., Berson, A., Degott, C., and Pessayre, D., 1991, Inhibition by salicylic acid of the activation and thus oxidation of long-chain fatty acids: Possible role in the development of Reye’s syndrome, J. Pharmacol. Exp. Ther. 259:894–904.PubMedGoogle Scholar
  15. Deschamps, D., De Beco, V, Fisch, C., Fromenty, B., Guillouzo, A., and Pessayre, D., 1994, Inhibition by perhexiline of oxidative phosphorylation and the β-oxidation of fatty acids: Possible role in pseudoalcoholic liver lesions, Hepatology 19:948–961.CrossRefPubMedGoogle Scholar
  16. DiMauro, S., and Schon, E. A., 1998, Nuclear power and mitochondrial disease, Nature Genet. 19:214–215.CrossRefPubMedGoogle Scholar
  17. Dong, W., Simeonova, P. P., Gallucci, R., Matheson, J., Fannin, R., Montuschi, P., Flood, L., and Luster, M. I., 1998, Cytokine expression in hepatocytes: Role of oxidative stress, J. Interferon Cytokine Res. 18:629–638.PubMedGoogle Scholar
  18. Dutertre, J. P., Bastides, F., Jonville, A. P., De Muret, A., Sonneville, A., Larrey, D., and Autret, E., 1991, Microvesicular steatosis after ketoprofen administration, Eur. J. Gastroenterol. Hepatol. 3:953–954.Google Scholar
  19. Ebert, E. C., Sun, E. A., Wright, S. H., Decker, J. P., Librizzi, R. J., Bolognese, R. J., and Lipshutz, W. H., 1984, Does early diagnosis and delivery in acute fatty liver of pregnancy lead to improvement in maternal and infant survival? Digest. Dis. Sci. 29:453–455.CrossRefPubMedGoogle Scholar
  20. Eisele, J. W., Barker, E. A., and Smuckler, E. A., 1975, Lipid content in the liver of fatty metamorphosis of pregnancy, Am. J. Pathol. 81:545–560.PubMedGoogle Scholar
  21. Esterbauer, H., Schaur, R. J., and Zollner, H., 1991, Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde, and related aldehydes, Free Radical Biol. Med. 11:81–128.CrossRefGoogle Scholar
  22. Fang, C., Lindros, K. O., Badger, T. M., Ronis, M. J. J., and Ingelman-Sundberg, M., 1998, Zonated expression of cytokines in rat liver: Effects of chronic ethanol and the cytochrome P450 2E1 inhibitor, chlormethiazole, Hepatology 27:1304–1310.CrossRefPubMedGoogle Scholar
  23. Farrell, G., 1994, Drug-Induced Liver Disease, Churchill-Livingstone, London.Google Scholar
  24. Fisch, C., Robin, M. A., Lettéron, P., Fromenty, B., Berson, A., Renault, S., Chachaty, C., and Pessayre, D., 1996, Cell-generated nitric oxide inactivates rat hepatocytes mitochondria in vitro but reacts with hemoglobin in vivo, Gastroenterology 110:210–220.CrossRefPubMedGoogle Scholar
  25. Forsyth, B. W., Horwitz, R. I., Acampora, D., Shapiro, E. D., Viscoli, C. M., Feinstein, A. R., Henner, R., Holabird, N. B., Jones, B. A., Karabelas, A. D. E., Kramer, M. S., Miclette, M., and Wells, J. A., 1989, New epidemiologic evidence confirming that bias does not explain the aspirin/Reye’s syndrome association, JAMA 261:2517–2524.CrossRefPubMedGoogle Scholar
  26. Fortgang, I. S., Belitsos, P. C., Chaisson, R. E., and Moore, R. D., 1995, Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy, Am. J. Gastroenterol. 90:1433–1436.PubMedGoogle Scholar
  27. Fréneaux, E., Labbe, G., Lettéron, P., Le Dinh, T., Degott, C., Genève, J., Larrey, D., and Pessayre, D., 1988, Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: Possible role in microvesicular steatosis induced by this antibiotic, Hepatology 8:1056–1062.PubMedGoogle Scholar
  28. Fréneaux, E., Fromenty, B., Berson, A., Labbe, G., Degott, C., Lettéron, P., Larrey, D., and Pessayre, D., 1988, Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial β-oxidation of fatty acids, J. Pharmacol. Exp. Ther. 255:529–535.Google Scholar
  29. Fromenty, B., and Pessayre, D., 1995, Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity, Pharmacol. Ther. 67:101–154.CrossRefPubMedGoogle Scholar
  30. Fromenty, B., Fréneaux, E., Labbe, G., Deschamps, D., Larrey, D., Lettéron, D., and Pessayre, D., 1989, Tianeptine, a new tricyclic antidepressant metabolized by β-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice, Biochem. Pharmacol. 38:3743–3751.CrossRefPubMedGoogle Scholar
  31. Fromenty, B., Fisch, C., Berson, A., Lettéron, P., Larrey, D., and Pessayre, D., 1990a, Dual effect of amiodarone on mitochondrial respiration: Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II, J. Pharmacol. Exp. Ther. 255:1377–1384.PubMedGoogle Scholar
  32. Fromenty, B., Fisch, C., Labbe, G., Degott, C., Deschamps, D., Berson, A., Lettéron, P., and Pessayre, D., 1990b, Amiodarone inhibits the mitochondrial β-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice, J. Pharmacol. Exp. Ther. 255:1371–1376.PubMedGoogle Scholar
  33. Fromenty, B., Lettéron, P., Fisch, C., Berson, A., Deschamps, D., and Pessayre, D., 1993, Evaluation of human blood lymphocytes as a model to study the effects of drugs on human mitochondria: Effects of low concentrations of amiodarone on fatty acid oxidation, ATP levels, and cell survival, Biochem. Pharmacol. 46:421–432.CrossRefPubMedGoogle Scholar
  34. Fromenty, B., Grimbert, S., Mansouri, A., Beaugrand, M., Erlinger, S., Rotig, A., and Pessayre, D., 1995, Hepatic mitochondrial DNA deletion in alcoholics: Association with microvesicular steatosis, Gastroentemlogy 108:193–200.Google Scholar
  35. Fromenty, B., Mansouri, A., Bonnefont, J. P., Courtois, F, Munnich, A., Rabier, D., and Pessayre, D., 1996, Most cases of medium-chain acyl-CoA dehydrogenase deficiency escape detection in France, Hum. Genet. 97:367–368.PubMedGoogle Scholar
  36. Fromenty, B., Berson, A., and Pessayre, D., 1997, Microvesicular steatosis and steatohepatitis: Role of mitochondrial dysfunction and lipid peroxidation, J. Hepatol. 26 (Suppl. 1):13–22.PubMedGoogle Scholar
  37. Galle, P. R., Hofmann, W. J., Walczak, H., Schaller, H., Otto, G., Stremmel, W., Krammer, P. H., and Runkell, L., 1995, Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage, J. Exp. Med. 182:1223–1230.CrossRefPubMedGoogle Scholar
  38. Genève, J., Hayat-Bonan, B., Labbe, G., Degott, C., Lettéron, P., Fréneaux, E., Le Dinh, T., Larrey, D., and Pessayre, D., 1987a, Inhibition of mitochondrial β-oxidation of fatty acids by pirprofen: Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug, J. Pharmacol. Exp. Ther. 242:1133–1137.PubMedGoogle Scholar
  39. Geneve, J., Larrey, D., Amouyal, G., Belghiti, J., and Pessayre, D., 1987b, Metabolic activation of the tricyclic antidepressant amineptine by human liver cytochrome P-450, Biochem. Pharmacol. 36:2421–2424.PubMedGoogle Scholar
  40. Giulivi, C., 1998, Functional implications of nitric oxide produced by mitochondria in mitochondrial metabolism, Biochem. J. 332:673–679.PubMedGoogle Scholar
  41. Glasgow, J. F. T., and Moore, R., 1993, Reye’s syndrome 30 years on: Possible marker of inherited metabolic disorders, Brit. Med. J. 307:950–951.PubMedGoogle Scholar
  42. Green, D. R., and Reed, J. C., 1998, Mitochondria and apoptosis. Science 281:1309–1312.PubMedGoogle Scholar
  43. Gregoriadis, G., and Sourkes, T. L., 1967, Intracellular distribution of copper in the liver of the rat, Can. J. Biochem. 45:1841–1851.PubMedGoogle Scholar
  44. Gressner, A. M., and Wulbrand, U, 1997, Variation in immunocytochemical expression of transforming growth factor (TGF)-beta in hepatocytes in culture and liver slices, Cell Tissue Res. 287:143–152.PubMedGoogle Scholar
  45. Grimbert, S., Fromenty, B., Fisch, C., Lettéron, P., Berson, A., Durand-Schneider, A. M., Feldmann, G., and Pessayre, D., 1993, Decreased mitochondrial oxidation of fatty acids in pregnant mice: Possible relevance to development of acute fatty liver of pregnancy, Hepatology 17:628–637.PubMedGoogle Scholar
  46. Grimbert, S., Fisch, C., Deschamps, D., Berson, A., Fromenty, B., Feldmann, G., and Pessayre, D., 1995, Effects of female sex hormones on liver mitochondria in non-pregnant female mice: Possible role in acute fatty liver of pregnancy, Am. J. Physiol. 268(Gastrointest. Liver Physiol. 31):G107–G115.Google Scholar
  47. Grislain, L., Gelé, P., Bertrand, M., Luijten, W., Bromet, N., Salvadori, C., and Kamoun, A., 1990, The metabolic pathways of tianeptine, a new antidepressant, in healthy volunteers, Drug Metab. Dispos. 18:804–808.PubMedGoogle Scholar
  48. Guigui, B., Perrot, S., Berry, J. P., Fleury-Feith, J., Martin, N., Métreau, J. M., Dhumeaux, D., and Zafrani, E. S., 1988, Amiodarone-induced hepatic phospholipidosis: A morphological alteration independent of pseudoal-coholic liver disease, Hepatology 8:1063–1068.PubMedGoogle Scholar
  49. Guzman, M., and Geelen, M. J. H., 1993, Regulation of fatty acid oxidation in mammalian liver, Biochim. Biophys. Acta 1167:227–241.PubMedGoogle Scholar
  50. Hautekeete, M. L., Degott, C., and Benhamou, J. P., 1990, Microvesicular steatosis of the liver, Acta Clin. Belg. 45:311–326.PubMedGoogle Scholar
  51. Heubi, J. E., Partin, J. C., Partin, J. S., and Schubert, W. K., 1987, Reye’s syndrome: Current concepts, Hepatology 7:155–164.PubMedGoogle Scholar
  52. Higuchi, M., Aggarwal, B. B., and Yeh, E. T. H., 1997, Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function, J. Clin. Invest. 99:1751–1758.PubMedGoogle Scholar
  53. Hoppel, C. L., Kerner, J., Turkaly, P., Turkaly, J., and Tandler, B., 1998, The malonyl-CoA-sensitive form of carnitine palmitoyltransferase is not localized exclusively in the outer membrane of rat liver mitochondria, J. Biol Chem. 273:23495–23503.CrossRefPubMedGoogle Scholar
  54. Hurwitz, E. S., Barrett, M. J., Bregman, D., Gunn, W. J., Schonberger, L. B., Fairweather, W. R., Drage, J. S., Lamontagne, J. R., Kaslow, R. A., Burlington, D. B., Quinnan, G. V, Parker, R. A., Phillips, K., Pinsky, P., Dayton, D., and Dowdle, W. R., 1985, Public health service study on Reye’s syndrome and medications: Report of the pilot phase, N. Engl. J. Med. 313:849–857.PubMedGoogle Scholar
  55. Ijlst, L., Wanders, R. J. A., Ushikubo, S., Kamijo, T, and Hashimoto, T., 1994, Molecular basis of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: Identification of the major disease-causing mutation in the β-subunit of the mitochondrial trifunctional protein, Biochim. Biophys. Acta 1215:347–350.PubMedGoogle Scholar
  56. Inayat-Hussain, S. H., Couet, C., Cohen, G. M., and Cain, K., 1997, Processing/activation of CPP32-like proteases is involved in transforming growth factor β1-induced apoptosis in rat hepatocytes, Hepatology, 25:1516–1526.CrossRefPubMedGoogle Scholar
  57. Isaacs, J. D., Sims, H. R, Powell, C. K., Bennett, M. J., Hale, D. E., Treem, W. R., and Strauss, A. W., 1996, Maternal acute fatty liver of pregnancy associated with fetal trifunctional protein deficiency: Molecular characterization of a novel maternal mutant allele, Pediat. Res. 40:393–398.PubMedGoogle Scholar
  58. Izai, K-., Uchida, Y., Orii, T., Yamamoto, S., and Hashimoto, T., 1992, Novel fatty acid β-oxidation enzymes in rat liver mitochondria: 1. Purification and properties of very long-chain acyl-coenzyme A dehydrogenase, J. Biol. Chem. 267:1027–1033.PubMedGoogle Scholar
  59. Kadiiska, M. B., Hanna, P. M., Jordan, S, J., and Mason, R. P., 1993, Electron spin resonance evidence for free radical generation in copper-treated vitamin E-and selenium-deficient rats: In vivo spin-trapping investigation, Mol. Pharmacol. 44:222–227.PubMedGoogle Scholar
  60. Kamimura, S., Gaal, K., Britton, R. S., Bacon, B. R., Triadafilopoulos, G., and Tsukamoto, H., 1992, Increased 4-hydroxynonenal levels in experimental alcoholic liver disease: Association of lipid peroxidation with liver fibrogenesis, Hepatology 16:448–453.PubMedGoogle Scholar
  61. Kaplan, M. M., 1985, Acute fatty liver of pregnancy, N. Engl. J. Med. 313:367–370.PubMedGoogle Scholar
  62. Kassahun, K., and Baillie, T. A., 1993, Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically active metabolite of valproic acid, in rat liver microsomal preparations, DrugMetab. Dispos. 21:242–248.Google Scholar
  63. Kassahun, K., Farrell, K., and Abbott, F., 1991, Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans, Drug Metab Dispos. 19:525–535.PubMedGoogle Scholar
  64. Kelly, D. P., Whelan, A. J., Ogden, M. L., Alpers, R., Zhang, Z., Bellus, G., Gregersen, N., Dorland, L., and Strauss, A. W., 1990, Molecular characterization of inherited medium-chain acyl-CoA dehydrogenase deficiency, Proc. Natl. Acad. Sci. USA 87:9236–9240.PubMedGoogle Scholar
  65. Killenberg, P. G., Davidson, E. D., and Webster, L. T., 1971, Evidence for a medium-chain fatty acid coenzyme A ligase (adenosine monophosphate) that activates salicylate, Mol. Pharmacol. 7:260–268.PubMedGoogle Scholar
  66. Kinosita, K., Yasuda, R., Noji, H., Ishiwata, S., and Yoshida, M., 1998, F1-ATPase: A rotary motor made of a single molecule, Cell 93:21–24.CrossRefPubMedGoogle Scholar
  67. Kodavanti, U. P., and Mehendale, H. M., 1990, Cationic amphiphilic drugs and phospholipid storage disorder, Pharmacol. Rev. 42:327–354.PubMedGoogle Scholar
  68. Krähenbühl, S., 1993, Alterations in mitochondrial function and morphology in chronic liver disease: Pathogenesis and potential for therapeutic intervention, Pharmacol. Ther. 60:1–38.PubMedGoogle Scholar
  69. Kurose, I., Higuchi, H., Kato, S., Miura, S., and Ishii, H., 1996, Ethanol-induced oxidative stress in the liver, Alcohol: Clin. Exp. Res. 20:77A–85A.Google Scholar
  70. Labbe, G., Fromenty, B., Fréneaux, E., Morzelle, V, Lettéron, P., Berson, A., and Pessayre, D., 1991, Effects of various tetracycline derivatives on in vitro and in vivo β-oxidation of fatty acids, egress of triglycerides from the liver, accumulation of hepatic triglycerides, and mortality in mice, Biochem. Pharmacol. 41:638–641.CrossRefPubMedGoogle Scholar
  71. Lai, K. K., Gang, D. L., Zawacki, J. K., and Cooley, T. P., 1991, Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI), Ann. Intern. Med. 115:283–284.PubMedGoogle Scholar
  72. Larrey, D., Tinel, M., Lettéron, P., Maurel, P., Loeper, J., Belghiti, J., and Pessayre, D., 1990, Metabolic activation of the new tricyclic antidepressant tianeptine by human liver cytochrome P-450, Biochem. Pharmacol. 40:545–550.CrossRefPubMedGoogle Scholar
  73. Latipăă, P. M., Kârki, T. T., Hiltunen, J. K., and Hassinen, I. E., 1986, Regulation of palmitoylcarnitine oxidation in isolated rat liver mitochondria: Role of the redox state of NAD(H), Biochim. Biophys. Acta 875:293–300.PubMedGoogle Scholar
  74. Lemasters, J. J., 1998, The mitochondrial permeability transition: From biochemical curiosity to pathophysiological mechanism, Gastroenterology 115:783–786.CrossRefPubMedGoogle Scholar
  75. Lettéron, P., Fromenty, B., Terris, B., Degott, C., and Pessayre, D., 1996, Acute and chronic hepatic steatosis leads to in vivo lipid peroxidation in mice, J. Hepatol. 24:200–208.CrossRefPubMedGoogle Scholar
  76. Lettéron, P., Brahimi-Bourouina, N., Robin, M. A., Moreau, A., Feldmann, G., and Pessayre, D., 1997, Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid β-oxidation, Am. J. Physiol. 272: (Gastrointest. Liver Physiol. 35):G1141–G1150.PubMedGoogle Scholar
  77. Lewis, W., and Dalakas, M. C., 1995, Mitochondrial toxicity of antiviral drugs, Nature Med. 1:417–422.PubMedGoogle Scholar
  78. Lewis, J. A., Huq, A., and Najarro, P., 1996a, Inhibition of mitochondrial function by interferon, J. Biol. Chem. 22:13184–13190.Google Scholar
  79. Lewis, W., Levine, E. S., Griniuviene, B., Tankersley, K. O., Colacino, J. M., Sommadossi, J. P., Watanabe, K. A., and Perrino, F. W., 1996b, Fialuridine and its metabolites inhibit DNA polymerase γ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts, Proc. Natl. Acad. Sci. USA 93:3592–3597.PubMedGoogle Scholar
  80. Lieber, C. S., 1994, Alcohol and the liver: 1994 update, Gastmentemlogy 106:1085–1105.Google Scholar
  81. Maddaiah, V. T., 1985, Ammonium inhibition of fatty acid oxidation in rat liver mitochondria: A possible cause of fatty liver in Reye’s syndrome and urea cycle defects, Biochem. Biophys. Res. Commun. 127:565–570.CrossRefPubMedGoogle Scholar
  82. Maddaiah, V. T., and Miller, P. S., 1989, Effects of ammonium chloride, salicylate, and carnitine on palmitic acid oxidation in rat liver slices, Pediat. Res. 25:119–123.PubMedGoogle Scholar
  83. Majamaa, K., Moilanen J. S., Uimonen, S., Remes, A. M., Salmela, P. I., Kărppâ, M., Majamaa-Voltti, K. A. M., Rusanen, H., Sorri, M., Peuhkurienen, K. J., and Hassinen, I. E., 1998, Epidemiology of the A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: Prevalence of the mutation in an adult population. Am. J. Human Genet. 63:447–454.Google Scholar
  84. Mansouri, A., Fromenty, B., Durand, F., Degott, C., Bernuau, J., and Pessayre, D., 1996, Assessment of the prevalence of genetic metabolic defects in acute fatty liver of pregnancy, J. Hepatol. 25:781.CrossRefPubMedGoogle Scholar
  85. Mansouri, A., Fromenty, B., Berson, A., Robin, M. A., Grimbert, S., Beaugrand, M., Erlinger, S., and Pessayre, D., 1997a, Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholic patients, J. Hepatol. 27:96–102.CrossRefPubMedGoogle Scholar
  86. Mansouri, A., Gaou, I., Fromenty, B., Berson, A., Lettéron, P., Degott, C., Erlinger, S., and Pessayre, D., 1997b, Premature oxidative aging of hepatic mitochondrial DNA in Wilson’s disease, Gastmentemlogy 113:599–605.Google Scholar
  87. Mansouri, A., Gaou, I., de Kerguenec, C., Amsellem, S., Haouzi, D., Berson, A., Moreau, A., Feldmann, G., Lettéron, P., and Pessayre, D., 1999, An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice, Gastmentemlogy 117:181–190.Google Scholar
  88. McGarry, J. D., and Brown, N. F, 1997, The mitochondrial carnitine palmitoyltransferase system: From concept to molecular analysis, Eur. J. Biochem. 244:1–14.CrossRefPubMedGoogle Scholar
  89. Miller, M. E., Brooks, J. G., Forbes, N., and Insel, R., 1992, Frequency of medium-chain acyl-CoA dehydrogenase deficiency G-985 mutation in sudden infant death syndrome, Pediat. Res. 31:305–307.PubMedGoogle Scholar
  90. Mitsuya, H., and Broder, S., 1986, Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type Ill/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides, Proc. Natl. Acad. Sci. USA 83:1911–1915.PubMedGoogle Scholar
  91. Morgan, M. Y., Reshef, R., Shah, R. R., Oates, N. S., Smith, R. L., and Sherlock, S., 1984, Impaired oxidation of debrisoquine in patients with perhexiline liver injury, Gut 25:1057–1064.PubMedGoogle Scholar
  92. Moriya, K., Yotsuyanagi, H., Shintani, Y., Fujie, H., Ishibashi, K., Matsuura, Y, Miyamura, T., and Koike, K., 1997, Hepatitis C virus core protein induces hepatic steatosis in transgenic mice, J. General Virol. 78:1527–1531.Google Scholar
  93. Moriya, K., Fujie, H., Shintani, Y, Yotsuyanagi, H., Tsutsumi, T., Ishibashi, K., Matsuura, Y, Kimura, S., Miyamura, T., and Koike, K., 1998, The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice, Nature Med. 4:1065–1067.PubMedGoogle Scholar
  94. Mŭller, M, Strand, S., Hug, H., Heninemann, E. A., Walczak, H., Hoffmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R., 1997, Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53, J. Clin. Invest. 99:403–413.PubMedGoogle Scholar
  95. Nada, M. A., Rhead, W. J., Sprecher, H., Schulz, H., and Roe, C. R., 1995, Evidence for intermediate channeling in mitochondria β-oxidation. J Biol. Chem. 270:530–535.PubMedGoogle Scholar
  96. Nagata, N., Matsuda, I., and Oyanagi, K., 1991, Estimated frequency of urea cycle enzymopathies in Japan, J. Med. Genet. 39:228–229.Google Scholar
  97. Naumann, M., and Scheidereit, C., 1994, Activation of NF-kB in vivo is regulated by multiple phosphorylations, EMBO J. 13:4597–4607.PubMedGoogle Scholar
  98. Neumann, M. C., Shear, N. H., Bellentani, S., and Tiribelli, C., 1998, Role of cytokines in ethanol-induced cytotoxicity in vitro in HepG2 cells, Gastroenterohgy 115:157–166.Google Scholar
  99. Nordmann, R., Ribière, C., and Rouach, H., 1992, Implication of free radical mechanisms in ethanol-induced cellular injury, Free Radical Biol. Med. 12:219–240.CrossRefGoogle Scholar
  100. Oikawa, S., and Kawanishi, S., 1996, Site-specific DNA damage induced by NADH in the presence of copper II: Role of active oxygen species, Biochemistry 35:4584–4590.CrossRefPubMedGoogle Scholar
  101. Okanoue, T., Sakamoto, S., Itoh, Y., Minami, M., Yasui, K., Sakamoto, M., Nishioji, K., Katagishi, T., Nakagawa, Y., Tada, H., Sawa, Y, Mizuno, M., Kagawa, K.., and Kashima, K., 1996, Side effects of high-dose interferon therapy for chronic hepatitis C, J. Hepatol. 25:283–291.CrossRefPubMedGoogle Scholar
  102. Partin, J. S., Daugherty, C. C., McAdams, A. J., Partin, J. C., and Schubert, W. K., 1984, A comparison of liver ultrastructure in salicylate intoxication and Reye’s syndrome, Hepatology 4:687–690.PubMedGoogle Scholar
  103. Pitkă;nen, S., and Robinson, B. H., 1996, Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase, J. Clin. Invest. 98:345–351.Google Scholar
  104. Ponchaut, S., Van Hoof, F., and Veitch, K., 1992, In vitro effects of valproate and valproate metabolites on mitochondria! oxidations: Relevance of CoA sequestration to the observed inhibitions, Biochem. Pharmacol, 43:2435–2442.PubMedGoogle Scholar
  105. Reinke, L. A., Moore, D. R., and McCay, P. B., 1997, Free radical formation in livers of rats treated acutely and chronically with alcohol. Alcohol: Clin. Exp. Res. 21:642–646.Google Scholar
  106. Remington, P. L., Rowley, D., McGee, H., Hall, W. N., and Monto, A. S., 1986, Decreasing trends in Reye syndrome and aspirin use in Michigan, 1979 to 1984, Pediatrics 77:93–98.PubMedGoogle Scholar
  107. Retèl, J., Hoebee, B., Braun, J. E. F., Lutgerink, J. T., Van den Akker, E., Wanamarta, A. H., Joenje, H., and Lafleur, M. V M., 1993, Mutational specificity of oxidative DNA damage, Mutat. Res. 299:165–182.PubMedGoogle Scholar
  108. Richter, C., Park, J. W., and Ames, B. N., 1988, Normal oxidative damage to mitochondrial DNA and nuclear DNA is extensive, Proc. Natl. Acad. Sci. USA 85:6465–6467.PubMedGoogle Scholar
  109. Ritter, S. J., and Davies, P. J. A., 1998, Identification of a transforming growth factor-β1/bone morphogenic protein 4 (TGF-β/BMP4) response element within tissue transglutaminase gene promoter, J. Biol. Chem. 273:12798–12806.CrossRefPubMedGoogle Scholar
  110. Rosmorduc, O., Richardet, J. P., Lageron, A., Munz, C., Callard, P., and Beaugrand, M., 1992, La stéatose hepatique massive: Une cause de décès brutal chez le malade alcoolique, Gastroenterol. Clin. Biol. 16:801–804.PubMedGoogle Scholar
  111. Rowe, P. C., Valle, D., and Brusilow, S. W., 1988, Inborn errors of metabolism in children referred with Reye’s syndrome: A changing pattern, JAMA 260:3167–3170.CrossRefPubMedGoogle Scholar
  112. Sadeque, A. J. M., Fisher M. B., Korzekwa, K. R., Gonzalez, F. J., and Rettie A. E., 1997, Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid, J. Pharmacol. Exp. Ther. 283:698–703.PubMedGoogle Scholar
  113. Sbarra, C., Castelli, M. G., Noseda, A., and Fanelli, R., 1981, Pharmacokinetics of amineptine in man, Eur. J. Drug Metab. Pharmacokinet. 6:123–126.PubMedGoogle Scholar
  114. Schon, E. A., Bonilla, E., and DiMauro, S., 1997, Mitochondrial DNA mutations and pathogenesis, J. Bioenerg. Biomembr. 29:131–149.CrossRefPubMedGoogle Scholar
  115. Schulz, H., 1991, Beta-oxidation of fatty acids, Biochim. Biophys. Acta 1081:109–120.PubMedGoogle Scholar
  116. Shan, B., Vazquez, E., and Lewis, J. A., 1990, Interferon selectively inhibits the expression of mitochondrial genes: A novel pathway for interferon-mediated responses, EMBO J. 9:4307–4314.PubMedGoogle Scholar
  117. Sims, H. F., Brackett, J. C., Powell, C. K., Treem, W. R., Hale, D. E., Bennett, M. J., Gibson, B., Shapiro, S., and Strauss, A. W., 1995, The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy, Proc. Natl. Acad. Sci. USA 92:841–845.PubMedGoogle Scholar
  118. Sokol, R. J., Twedt, D., McKim, J. M., Devereaux, M. W., Karrer, F. M., Kam, I., Von Steigman, G., Narkewicz, M. R., Bacon, B. R., Britton, R. S., and Neuschwander-Tetri, B. A., 1994, Oxidant injury to hepatic mitochondria in patients with Wilson’sdisease and Bedlington terriers with copper toxicosis, Gastroenterology 107:1788–1798.PubMedGoogle Scholar
  119. Somasundaran, M., Zapp, M. L., Beattie, L. K., Pang, L., Byron, K. S., Bassell, G. J., Sullivan, J. L., and Singer, R. H., 1994, Localization of HIV RNA in mitochondria of infected cells; Potential role in cytopathogenicity, J. Cell. Biol. 126:1353–1360.CrossRefPubMedGoogle Scholar
  120. Strand, S., Hefmann, W. J., Grambihler, A., Hug, H., Volkmann, M., Otto, G., Wesch, H., Mariani, S. M., Hack, V., Stremmel, W, Krammer, P. H., and Galle, P. R., 1998, Hepatic failure and liver cell damage in acute Wilson’s disease involve CD95 (APO-1/Fas) mediated apoptosis, Nature Med. 4:588–593.PubMedGoogle Scholar
  121. Susin, S. A., Zamzami, N., and Kroemer, G., 1998, Mitochondria as regulators of apoptosis: Doubt no more, Biochim. Biophys. Acta 1366:151–165.PubMedGoogle Scholar
  122. Takahashi, T., Tanaka, M., Inazawa, J., Abe, T., Suda, T., and Nagata, S., 1994, Human Fas ligand: Gene structure, chromosomal location, and species specificity, Int. Immunol. 6:1567–1574.PubMedGoogle Scholar
  123. Tennant, B. C., Baldwin, B. H., Graham, L. A., Ascenzi, M. A., Hombuckle, W. E., Rowland, P. H., Tochkov, I. A., Yeager, A. E., Erb, H. N., Colacino, J. M., Lopez, C., Engelhardt, J. A., Bowsher, R. R., Richardson, F. C., Lewis, W, Cote, P. J., Korba, B. E., and Gerin, J. L., 1998, Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection, Hepatology 28:179–191.CrossRefPubMedGoogle Scholar
  124. Thomas, G. R., Forbes, J. R., Roberts, E. A., Walshe, J. M., and Cox, D. W, 1995, The Wilson disease gene: Spectrum of mutations and their consequences, Nature Genet. 9:210–217.CrossRefPubMedGoogle Scholar
  125. Tonsgard, J. H., and Getz, G. S., 1985, Effect of Reye’s syndrome serum on isolated chinchilla liver mitochondria, J. Clin. Invest. 76:816–825.PubMedGoogle Scholar
  126. Treem, W. R., Rinaldo, P., Hale, D. E., Stanley, C. A., Millington, D. S., Hyams, J. S., Jackson, S., and Turnbull, D. M., 1994, Acute fatty liver of pregnancy and long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency, Hepatology 19:339–345.CrossRefPubMedGoogle Scholar
  127. Treem, W. R., Shoup, M. E., Hale, D. E., Bennett, M. J., Rinaldo, P., Millington, D. S., Stanley, C. A., Riely, C. A., and Hyams, J. S., 1996, Acute fatty liver of pregnancy, hemolysis, elevated liver enzymes, and low platelets syndrome, and long chain 3-hydroxyacyl-Coenzyme A dehydrogenase deficiency, Am. J. Gastroenterol. 91:2293–2300.PubMedGoogle Scholar
  128. Trejo-Skalli, A. V, Velasco, P. T., Murthy, S. N. P., Lorand, L., and Goldman, R. D., 1995, Association of a transglutarninase-related antigen with intermediate filaments, Proc. Natl. Acad. Sci. USA 92:8940–8944.PubMedGoogle Scholar
  129. Trost, L. C., and Lemasters, J. J., 1996, The mitochondrial permeability transition: A new pathophysiological mechanism for Reye’s syndrome and toxic liver injury, J. Pharmacol. Exp.Ther. 278:1000–1005.PubMedGoogle Scholar
  130. Trost, L. C., and Lemasters, J. J, 1997, Role of the mitochondrial permeability transition in salicylate toxicity to cultured rat hepatocytes: Implications for the pathogenesis of Reye’s syndrome, Toxicol. Appl. Pharmacol. 147:431–441.CrossRefPubMedGoogle Scholar
  131. Turnbull, D. M., Bone, A. J., Bartlett, K., Koundakjian, P. P., and Sherratt, H. S. A., 1983, The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats, Biochem. Pharmacol. 32:1887–1892.CrossRefPubMedGoogle Scholar
  132. Uchida, T., Kao, H., Quispe-Sjogren, M., and Peters, R. L., 1983, Alcoholic foamy degeneration: A pattern of acute alcoholic injury of the liver, Gastroenterology 84:683–692.PubMedGoogle Scholar
  133. Uchida, Y., Izai, K., Orii, T., and Hashimoto, T., 1992, Novel fatty acid β-enzymes in rat liver mitochondria: II. Purification and properties of enoyl-coenzyme A (CoA) hydratase/3-hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase trifunctional protein, J. Biol. Chem. 267:1034–1041.PubMedGoogle Scholar
  134. Victorino, R. M., Silveira, J. C., Baptista, A., and De Moura, M. C., 1980, Jaundice associated with naproxen, Postgrad. Med. J. 56:368–370.PubMedGoogle Scholar
  135. Wieland, P., and Lauterburg, B. H., 1995, Oxidation of mitochondrial proteins and DNA following administration of ethanol, Biochem. Biophys. Res. Commun. 213:815–819.CrossRefPubMedGoogle Scholar
  136. Wilcken, B., Leung, K. C., Hammond, J., Kamath, R., and Leonard, J. V, 1993, Pregnancy and fetal long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency, Lancet 341:407–408.CrossRefPubMedGoogle Scholar
  137. Williams, M. D., Van Remmen, H., Conrad, C. C., Huang, T. T, Epstein, C. J., and Richardson, A., 1998, Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice, J. Biol. Chem. 273:28510–28515.PubMedGoogle Scholar
  138. Wojtczak, L., and Schönfeld, P., 1993, Effect of fatty acids on energy coupling processesin mitochondria, Biochim. Biophys. Acta 1183:41–57.PubMedGoogle Scholar
  139. Yakes, F. M., and Van Houten, B., 1997, Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress, Proc. Natl. Acad. Sci. USA 94:514–519.CrossRefPubMedGoogle Scholar
  140. Yarchoan, R., Mitsuya, H., Myers, C. E., and Broder, S., 1989, Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides, N. Engl. J. Med. 321:726–738.PubMedGoogle Scholar
  141. Yokota, I., Saijo, T, Vockley, J., and Tanaka, K., 1992, Impaired tetramer assembly of variant medium-chain acylcoenzyme A dehydrogenase with a glutamate or aspartate substitution for lysine 304 causing instability of the protein, J. Biol. Chem. 267:26004–26010.PubMedGoogle Scholar
  142. Zatloukal, K., Böck, G., Rainer, I., Denk, H., and Weber, H., 1991, High molecular weight components are main constituents of Mallory bodies isolated with a fluorescence activated cell sorter, Lab. Invest. 64:200–206.PubMedGoogle Scholar
  143. Zhang, Z., Kolvraa, S., Zhou, Y, Kelly, D. P., Gregersen, N., and Strauss, A. W., 1993, Three RFLPs defining a haplotype associated with the common mutation in human medium-chain acyl-CoA dehydrogenase (MCAD) deficiency occur in Alu repeats, Am. J. Hum. Genet. 52:1111–1121.PubMedGoogle Scholar
  144. Zhang-Gouillon, Z. Q., Yuan, Q. X., Hu, B., Marceau, N., French, B. A., Gaal, K., Nagao, Y., Wan, Y. J. Y., and French, S. W, 1998, Mallory body formation by ethanol feeding in drug-primed mice, Hepatology 27:116–122.CrossRefPubMedGoogle Scholar
  145. Zimmerman, H. J., 1978, Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, Appleton-Century-Crofts, New YorkGoogle Scholar
  146. Zimmerman, H. J., 1981, Effects of aspirin and acetaminophen on the liver, Arch. Intern. Med. 141:333–342.CrossRefPubMedGoogle Scholar
  147. Immerman, H. J., and Ishak, K. G., 1982, Valproate-induced hepatic injury: Analyses of 23 fatal cases, Hepatology 2:591–597.Google Scholar
  148. Zoulim, F., and Trépo, C., 1994, Nucleoside analogs in the treatment of chronic viral hepatitis: Efficiency and complications, J. Hepatol. 21:142–144.CrossRefPubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Dominique Pessayre
    • 1
  • Bernard Fromenty
    • 1
  • Abdellah Mansouri
    • 1
  1. 1.INSERM U 481Hôpital BeaujonClichyFrance

Personalised recommendations